TY - JOUR
T1 - Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach
AU - Ocean, Allyson J.
AU - Christos, Paul
AU - Sparano, Joseph A.
AU - Shah, Manish A.
AU - Yantiss, Rhonda K.
AU - Cheng, Jonathan
AU - Lin, Juan
AU - Papetti, Michael
AU - Matulich, Dan
AU - Schnoll-Sussman, Felice
AU - Besanceney-Webler, Christen
AU - Xiang, Jenny
AU - Ward, Maureen
AU - Dilts, Kaili Temple
AU - Keresztes, Roger
AU - Holloway, Shannon
AU - Chen, Eric X.
AU - Wright, John J.
AU - Lane, Maureen E.
N1 - Funding Information:
Acknowledgments The authors acknowledge the late Dr. Scott Wadler, our colleague and friend, who conceived of and designed this trial and founded the New York Cancer Consortium. He will be remembered for his skills as clinician, scholar, and mentor. This work was supported by the National Institute of Health, National Cancer Institute (N01-CM-62204, PI: Joseph A. Sparano and P30CA013330, PI: David Goldman, MD).
PY - 2014/6
Y1 - 2014/6
N2 - Purpose: To determine the effectiveness of bortezomib plus irinotecan and bortezomib alone in patients with advanced gastroesophageal junction (GEJ) and gastric adenocarcinoma. We also sought to explore the effect of these therapeutics on tumor and normal gene expression in vivo. Methods: Forty-one patients with advanced GEJ (89 %) or gastric (11 %) adenocarcinoma received bortezomib (1.3 mg/m2 days 1, 4, 8, 11) plus irinotecan (125 mg/m2 days 1, 8) every 21 days as first line therapy (N=29), or bortezomib alone as second line therapy (N=12). The trial was designed to detect a 40 % response rate for the combination, and 20 % response rate for bortezomib alone. Affymetrix HU133A gene chip arrays were used for gene expression studies. Results: Objective response occurred in 3 of 29 patients (10 %, 95 % confidence intervals [CI] 2 %, 27 %) treated with bortezomib plus irinotecan, and in 1 of 12 patients (8 %, 95 % CI 0 %, 39 %) with bortezomib alone. Due to the limited number of responders, there were no significant correlations with response found in the gene expression profiles of 12 patients whose tumors were sampled before and 24 h after therapy with bortezomib alone (N=2) or the combination (N=10). Conclusions: We conclude that bortezomib is not effective for the treatment of advanced adenocarcinoma of the GEJ or stomach, whether used alone or in combination with irinotecan, in an unselected patient population.
AB - Purpose: To determine the effectiveness of bortezomib plus irinotecan and bortezomib alone in patients with advanced gastroesophageal junction (GEJ) and gastric adenocarcinoma. We also sought to explore the effect of these therapeutics on tumor and normal gene expression in vivo. Methods: Forty-one patients with advanced GEJ (89 %) or gastric (11 %) adenocarcinoma received bortezomib (1.3 mg/m2 days 1, 4, 8, 11) plus irinotecan (125 mg/m2 days 1, 8) every 21 days as first line therapy (N=29), or bortezomib alone as second line therapy (N=12). The trial was designed to detect a 40 % response rate for the combination, and 20 % response rate for bortezomib alone. Affymetrix HU133A gene chip arrays were used for gene expression studies. Results: Objective response occurred in 3 of 29 patients (10 %, 95 % confidence intervals [CI] 2 %, 27 %) treated with bortezomib plus irinotecan, and in 1 of 12 patients (8 %, 95 % CI 0 %, 39 %) with bortezomib alone. Due to the limited number of responders, there were no significant correlations with response found in the gene expression profiles of 12 patients whose tumors were sampled before and 24 h after therapy with bortezomib alone (N=2) or the combination (N=10). Conclusions: We conclude that bortezomib is not effective for the treatment of advanced adenocarcinoma of the GEJ or stomach, whether used alone or in combination with irinotecan, in an unselected patient population.
KW - Adenocarcinoma
KW - Bortezomib
KW - Combination therapy
KW - Gastroesophageal junction
KW - Irinotecan
KW - Microarray
KW - Proteasome inhibitor
UR - http://www.scopus.com/inward/record.url?scp=84904619368&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904619368&partnerID=8YFLogxK
U2 - 10.1007/s10637-014-0070-0
DO - 10.1007/s10637-014-0070-0
M3 - Article
C2 - 24526575
AN - SCOPUS:84904619368
SN - 0167-6997
VL - 32
SP - 542
EP - 548
JO - Investigational New Drugs
JF - Investigational New Drugs
IS - 3
ER -